Treatment of Thrombocytopenia in Patients With Chronic Hepatitis C: Potential Impact on Treatment Candidacy and Outcomes

In this new Treatment Update, CCO’s expert faculty members provide an overview of current approaches to the management and prevention of thrombocytopenia in the context of hepatitis C.

Now Available!

CME-Certified Module:

Coming Soon!

CME-Certified Interactive Virtual Presentation:

2008 AASLD Meeting

CCO's official conference coverage of the 2008 AASLD meeting includes Capsule Summaries of key presentations, as well as Expert Analyses, Slides, Expert Recaps, and audio and video Expert Highlights that focus on key issues highlighted at the conference.

• Advances in HBV Treatment With Approved Agents
• 2008 Update on the Use of Approved HCV Agents
• Focus on Investigational HBV/HCV Agents

Now Available!

CME-Certified Expert Analysis:

Advances in HBV Treatment With Approved Agents Join Jules L. Dienstag, MD; Robert G. Gish, MD; and Ira M. Jacobson, MD, as they discuss data presented at the 2008 AASLD Meeting on advances in the use of currently approved therapies for the treatment of chronic hepatitis B infection.

Downloadable Slidesets:
HBV Expert Recap of AASLD 2008
This downloadable slideset reviews the most clinically relevant new data on hepatitis B approved and investigational therapies presented at the 2008 American Association for the Study of Liver Diseases Meeting.

HCV Expert Recap of AASLD 2008
This downloadable slideset reviews key data on investigational agents and predictors of response with approved agents for the treatment of hepatitis C presented at the 2008 American Association for the Study of Liver Diseases Meeting.

HBV Providers’ Choice in Prime Time: Addressing Issues of Patient Populations, Resistance, Individualized Treatment, Management, and Efficacy

CCO’s expert faculty members review recent data on pertinent issues in HBV treatment including management of HBV in the setting of pregnancy, the role of initial regimen selection in preventing resistance and virologic breakthrough, and the management of patients with partial response to therapy.

Now Available!

CME/CE-Certified Virtual Presentations:

HBV Patient Populations: Treating Hepatitis B in the Setting of Pregnancy Join Heiner Wedemeyer, MD, as he reviews HBV infection management in the setting of pregnancy and potential pregnancy. Downloadable PowerPoint slideset available for review and use in your own educational presentations.

Efficacy, Resistance, and Durability Join Stephen Locarnini, MD, PhD, FRC (Path), as he discusses current concepts on how to best avoid antiviral resistance to initial HBV therapies. Downloadable PowerPoint slideset available for review and use in your own educational presentations.

Management of Suboptimal Response Join Ching-Lung Lai, MD, as he reviews strategies to identify and manage incomplete response in HBV-infected patients receiving treatment with oral antiviral therapies. Downloadable PowerPoint slideset available for review and use in your own educational presentations.

Cases in Point: Risk Factors, Surveillance Strategies, and Treatment Options for Hepatocellular Carcinoma 

Now Available!

Downloadable Slideset:

Cases in Point: Risk Factors, Surveillance Strategies, and Treatment Options for Hepatocellular Carcinoma Review monitoring and surveillance recommendations for HCC and emerging strategies for treatment and management, then download slides for use in your own self-study or presentations.

Management of Depression and HCV: Novel Data, Best Practices, and Case Challenges

CME-Certified Modules:

Clinical Data and Best Practices for Managing Depression in HCV-Infected Patients Treated With Peginterferon and Ribavirin Martin Schaefer, MD, highlights management strategies for patients with hepatitis C virus infection and depression, highlighting new studies from the past year.

Answering the Questions: Depression Related to HCV and Its Treatment Alfredo Alberti, MD; Lucia Gallego, MD; Michael R. Kraus, MD, PhD; and Vicente Soriano, MD, PhD, provide practical answers to frequently asked questions about diagnosing and managing depression before and during HCV treatment.

CME-Certified Slideset Modules:

• Clinical Data and Best Practices for Managing Depression in HCV-Infected Patients Treated With Peginterferon and Ribavirin
  In this slideset module, Martin Schaefer, MD, discusses the relationships among depression, hepatitis C virus, and treatment; management strategies for depression; the effects of hepatitis C virus on cognitive function; and management of psychiatric disorders in the setting of drug addiction.
  
• Answering the Questions: Depression Related to HCV and Its Treatment
  In this slideset module, Michael R. Kraus, MD, PhD, addresses the most relevant questions pertaining to the clinical management of depressive symptoms in HCV-infected patients.

CME-Certified Interactive Case Challenges and accompanying Expert Viewpoints:

	Management of a 43 Year-Old HCV-Infected, Treatment-Naive Female With a History of Major Depression Join Charles L. Raison, MD, in choosing the optimal treatment strategies for a woman with recently diagnosed hepatitis C virus infection and a history of major depression.
	Expert Viewpoint by Patrick Marcellin, MD: Regional Perspectives on the Management of Depression Prior to HCV Therapy

	Management of a Patient Without a History of Depression Who Develops Psychiatric Complications During HCV Therapy Mark S. Sulkowski, MD, discusses factors to consider when psychiatric disorders develop in patients treated for chronic hepatitis C.
	Expert Viewpoint by Martin Schaefer, MD: Regional Perspectives on the Management of a Patient Without a History of Depression Who Develops Psychiatric Complications During HCV Therapy

	Management of Emergent Depression and Suicidal Ideation During HCV Therapy Join Alfredo Alberti, MD, in choosing the optimal treatment strategies for a woman who develops depressive symptoms during HCV therapy, despite the absence of symptoms at treatment baseline.
	Expert Viewpoint by Michael R. Kraus, MD, PhD: Regional Perspectives on the Management of Emergent Depression and Suicidal Ideation During HCV Therapy

Minimizing Barriers and Maximizing Response: Strategies and Tools for Frontline Providers Caring for Patients With Chronic Hepatitis C

Interesting Interactive Case Challenges and Virtual Presentations that explore treatment decisions for patients with chronic hepatitis C.

• Minimizing Barriers and Maximizing Response: Strategies and Tools for Frontline Providers Caring for Patients With Chronic Hepatitis C
  Michael W. Fried, MD, discusses strategies to tailor hepatitis C virus treatment according to a patient’s individual response.
  
  
• Tailoring HCV Treatment to Patients With Advanced Liver Disease
  Join Douglas M. Heuman, MD, FACP, as he discusses the impact of advanced fibrosis and cirrhosis on treatment approaches for HCV infection.
  
  
• Managing the Difficult-to-Treat HCV Patient
  K. Rajender Reddy, MD, discusses considerations for the management of HCV-infected patients who are nonresponders or relapsers to previous HCV therapy.

Interactive Decision Support Tools:

	HCV Drug Dose and Response
	Key Questions for Patients Facing HCV Retreatment

Hepatitis Annual Update 2008

Clinical Care Options' Hepatitis Annual Update offers the latest information across a wide range of hepatic issues for the optimal clinical management of your patients. Expert faculty members prepared the following CME-certified educational modules that are now available on the CCO Web site:

• Can Hepatitis B Be Cured?
• Therapy of Chronic Hepatitis B: Who to Treat and When to Treat? A Case-Based Discussion
• Therapy of Chronic Hepatitis B: What to Choose, When to Change, and When to Stop
• New Data on Currently Available Hepatitis C Therapies and Their Impact on Initial Treatment Strategies
• Strategies for Management of Hepatitis C Treatment Failure
• HCV Therapy: What Will the Future Look Like?
• Update on Autoimmune Hepatitis: Management Strategies
• Managing the Complications of Cirrhosis
• Hepatitis Journal Club: Top Clinical Articles of 2007-08

New Options for HCV Nonresponders: Navigating Emerging Data and Best Practices for Treatment-Experienced Patients

This Treatment Update is specifically designed for frontline providers, nurse practitioners, physician assistants, and others who treat patients who have been previously treated for HCV. It provides program participants with the latest data and best practices on management approaches for these patients as well as a means to synthesize these strategies through Interactive Case Challenges.

Part 1 - Management of Previous HCV Treatment Nonresponders

CME-Certified Virtual Presentation:
Management of HCV Nonresponders
Join Ira M. Jacobson, MD, as he discusses treatment strategies for the optimal management of patients with chronic hepatitis C with previous nonresponse to antiviral therapy.

Downloadable Slideset:
Management of HCV Nonresponders
Download and review key data selected by Ira M. Jacobson, MD, on the retreatment of patients with a previous nonresponse to HCV therapy. Use the slides for self-study and in your own presentations!

Part 2 - Optimizing and Individualizing HCV Retreatment

CME-Certified Virtual Presentation:
Maintaining Patients on Treatment: Optimizing and Individualizing Retreatment for Success
Join Bruce R. Bacon, MD, as he discusses strategies for maintaining therapy in patients who are being retreated for hepatitis C.

Downloadable Slideset:
Maintaining Patients on Treatment: Optimizing and Individualizing Retreatment for Success
Download and review key data selected by Bruce R. Bacon, MD, on optimizing and individualizing retreatment with available agents in patients with a previous suboptimal response to HCV therapy. Use the slides in your own presentations!

• HBV Core Curriculum 2008
  Join Robert G. Gish, MD, as he discusses the epidemiology and natural history of HBV. Then listen as Albert D. Min, MD, discusses the treatment and management of chronic hepatitis B virus infection.
  
  
  
• HBV Election 2008: Meet the Clinical Candidates
  Tram T. Tran, MD, and Robert S. Brown, Jr., MD, MPH, discuss new agents for the treatment of chronic hepatitis B and how they might fit in the treatment landscape. 
  
   
• On-Treatment Management Strategies for Chronic Hepatitis B
  Along with Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, choose management strategies for a patient with chronic hepatitis B receiving treatment with adefovir. Then, join Ira M. Jacobson, MD, as he reviews on-treatment hepatitis B virus guidelines including the relationships between early responses to oral anti-hepatitis B virus agents and future treatment outcomes.
  
  
  
• Drug Resistance in Chronic Hepatitis B: From Definitions to Management Strategies
  Access an educational module and Virtual Presentation from Emmet B. Keeffe, MD, MACP and Paul Martin, MD.
  
  

• 2008 Annual Meeting of the American Association for the Study of Liver Diseases
  
• 2008 Conference on Hepatitis B and C Virus Resistance to Antiviral Therapies
  
• 2008 Annual Meeting of the European Association for the Study of the Liver*
  

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

• Management of a Patient With Hepatitis C Genotype 1 Infection Who Relapsed After a Course of Standard Interferon and Ribavirin
  Join Tiffany A. Geahigan, PA-C, CCRC, in choosing the optimal treatment strategies for an obese black patient with genotype 1 hepatitis C who relapsed after a course of standard-dose interferon alfa and ribavirin.
  
  
• Retreatment of a Patient Failing Previous HCV Therapy 
  Anne Croghan, MN, ARNP, discusses treatment options and predictors of response for patients relapsing on previous peginterferon/ribavirin therapy.
  
  
• Management of an HCV-Infected Male With Advanced Liver Disease 
  Gregory T. Everson, MD, FACP, discusses management strategies for a patient with advanced hepatitis C.
  
  
• Optimizing Treatment Success of a Second HCV Regimen in a Patient With Unsuccessful Initial Treatment With Peginterferon alfa-2a and Ribavirin
  Robert Gish, MD, discusses management strategies for a patient predisposed to anemia and depression.
  
  
• Treatment of a Genotype 1a Patient Not Achieving Full Virologic Suppression With Peginterferon/Ribavirin at 24 Weeks
  Maria H. Sjogren, MD, MPH, FACP, discusses the treatment management options for patients not achieving HCV RNA suppression by 24 weeks of peginterferon alfa-2b/ribavirin treatment.
  
  
• On-Treatment Management of a Patient With Chronic Hepatitis B Receiving Adefovir Therapy

Topics

• Fibrosis and Cirrhosis
• HBV
• HCV
• Hepatocellular Carcinoma
• HIV Coinfection
• Nash, ALD, etc.
• Other Hepatitis Viruses
• Transplantation

Resources

• Advanced Search
• Case Challenges
• Animations
• Live Events
• Slide Download Library
• Interactive Tools
• Bookstore

13th International Symposium on Viral Hepatitis and Liver Disease

March 20-24, 2009, Washington, DC

The 13th ISVHLD will commemorate progress made in the global fight against viral hepatitis and liver disease and focus the field's attention on the key future challenges. The meeting will be jointly sponsored by the American Association for the Study of Liver Diseases (AASLD) and the National Institutes of Health (NIH).

Registration is Now Open!
Click here for more information and to register today.

VIDEO HIGHLIGHTS FROM AASLD 2008
Approved HCV Agents

Gregory T. Everson, MD, FACP, discusses data from AASLD 2008 on strategies for improving hepatitis C treatment response with approved agents and predicting response based on various possible responses and assays. Click here to start.

Clevudine Provides Greater Viral Suppression and HBeAg Seroconversion vs Lamivudine in HBeAg-Positive Chronic Hepatitis B at 48 Weeks  

Switching at Week 48 from lamivudine to clevudine associated with additional virologic suppression in patients with HBeAg-positive chronic hepatitis B.


Click here for related Capsule Summaries.

Click here for the slide library.

Click here to visit the bookstore.

 

This important resource is based on the proceedings of the 6th Annual
Clinical Care Options Hepatitis Symposium and was written by the
presenting faculty members. This program is jointly sponsored by
Postgraduate Institute for Medicine and Clinical Care Options.

Regular price: $29.99
Sale Price: $25.99

Click here for more information and to order this important book.

Mark S. Sulkowski, MD, discusses factors to consider when psychiatric disorders develop in patients treated for chronic hepatitis C.

Click here for more cases.

Click here for more tools.